Estimation of symptom-free days in generalized anxiety disorder

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. [text revision]. Washington (DC): American Psychiatric Association; 2000
   Google Scholar
• Arikian SR, Gorman JM. A review of the diagnosis, pharmacologic treatment, and economic aspects of anxiety disorders. Primary Care Companion J Clin Psychiatry 2001;3(3):110–7
   PubMedGoogle Scholar
• Woodman CL, Breen K, Noyes Jr R, et al. The relationship between irritable bowel syndrome and psychiatric illness. A family study. Psychosomatics 1998;39(1):45–54
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry 2001;62\(Suppl 11):15–9 [discussion 20–1]
   Google Scholar
• Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys’ estimates. Arch Gen Psychiatry 2002;59(2):115–23
   PubMed Web of Science ®Google Scholar
• Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry 2001;62(Suppl 19):11–9
   PubMedGoogle Scholar
• Sheehan DV. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. J Clin Psychiatry 2001;62(Suppl 19):26–31
   PubMedGoogle Scholar
• Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001;62(Suppl 12):5–9
   PubMed Web of Science ®Google Scholar
• Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998;55(7):645–51
   PubMed Web of Science ®Google Scholar
• Mallick R, Chen J, Entsuah AR, Schatzberg AF. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. J Clin Psychiatry 2003;64(3):321–30
   PubMed Web of Science ®Google Scholar
• Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60(8):528–35
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157(6): 968–74
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. J Am Med Assoc 2000;283(23):3082–8
   Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15–22
   Google Scholar
• Katz IR, Reynolds III CF, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002;50:18–25
   PubMed Web of Science ®Google Scholar
• Hackett D. Venlafaxine XR in the treatment of anxiety. Acta Psychiatr Scand Suppl 2000;(406):30–5
   Google Scholar
• Kelsey JE. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. Depression Anxiety 2000;12 (Suppl 1):81–4
   PubMedGoogle Scholar
• Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60(Suppl 22):29–34
   PubMedGoogle Scholar
• Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994;51(5):355–64
   PubMed Web of Science ®Google Scholar
• Andrews G, Sanderson K, Slade T, Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bull WHO 2000;78(4):446–54
   PubMed Web of Science ®Google Scholar
• Feldstein ML. Quality-of-life-adjusted survival for comparing cancer treatments. A commentary on TWiST and Q-TWiST. Cancer 1991;67(Suppl 3):851–4
   Google Scholar
• Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995;17(1):136–53
   PubMed Web of Science ®Google Scholar
• Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997;12(2 pt 2):286–96
   Google Scholar
• Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CS. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry 2001;58(2):181–7
   PubMed Web of Science ®Google Scholar
• Simon GE, Katon WJ, VonKorff M, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry 2001;158(10):1638–44
   PubMed Web of Science ®Google Scholar
• Simon GE, Von Korff M, Ludman EJ, et al. Cost-effectiveness of a program to prevent depression relapse in primary care. Med Care 2002;40(10):941–50
   PubMed Web of Science ®Google Scholar
• Liu CF, Hedrick SC, Chaney EF, et al. Cost-effectiveness of collaborative care for depression in a primary care veteran population. Psychiatr Serv 2003;54(5):698–704
   PubMed Web of Science ®Google Scholar
• Katon WJ, Roy-Byrne P, Russo J, Cowley D. Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psychiatry 2002;59(12):1098–104
   PubMed Web of Science ®Google Scholar